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ABSTRACT: Background: Amyloid deposition is
common in dementia with Lewy bodies, but its patho-
physiological significance is unclear.
Objective: The objective of this study was to investi-
gate the relationship between amyloid deposition and
clinical profile, gray matter volume, and brain perfusion
in dementia with Lewy bodies.
Methods: Dementia with Lewy bodies (n537), Alz-
heimer’s disease (n520), and controls (n520) under-
went a thorough clinical assessment, 3T MRI, and
early- and late-phase 18F-Florbetapir PET-CT to assess
cortical perfusion and amyloid deposition, respectively.
Amyloid scans were visually categorized as positive or
negative. Image analysis was carried out using statisti-
cal parametric mapping (SPM) 8.
Results: There were no significant differences between
amyloid-positive and amyloid-negative dementia with Lewy
bodies cases in age (P5.78), overall cognitive impairment
(P5.83), level of functional impairment (P5.80), or any
other clinical or cognitive scale. There were also no
significant differences in hippocampal or gray matter vol-
umes. However, amyloid-positive dementia with Lewy bod-
ies cases had lower medial temporal lobe perfusion
(P5.03) than amyloid-negative cases, although a combina-
tion of medial temporal lobe perfusion, hippocampal vol-
ume, and cognitive measures was unable to accurately
predict amyloid status in dementia with Lewy bodies.
Conclusions: Amyloid deposition was not associated
with differences in clinical or neuropsychological profiles in
dementia with Lewy bodies, but was associated with imag-
ing evidence of medial temporal lobe dysfunction. The
presence of amyloid in dementia with Lewy bodies cannot
be identified on the basis of clinical and other imaging fea-
tures and will require direct assessment via PET imaging or
CSF. VC 2018 The Authors. Movement Disorders published
by Wiley Periodicals, Inc. on behalf of International Parkin-
son and Movement Disorder Society.
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Dementia with Lewy bodies (DLB) is the second
most common type of neurodegenerative dementia.
When compared with Alzheimer’s disease (AD), it is
associated with distinct cognitive, neuropsychiatric,
and motor symptoms and characteristic imaging
findings.1
The pathological hallmarks of DLB are the presence
of Lewy bodies and Lewy neurites, but many cases
also display AD pathology postmortem.2 However,
the importance of concurrent AD pathology in DLB,
at what point during the disease it occurs, and its rela-
tionships to clinical presentations are unclear.3 Posi-
tron emission tomography (PET) amyloid imaging
allows the investigation of these relationships in vivo.
In addition, as a result of the lipophilic nature of amy-
loid ligands such as Florbetapir, images collected
immediately postinjection depict blood perfusion dis-
tribution.4 This allows comparison of amyloid deposi-
tion and perfusion without the need for an additional
scan.
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We examined amyloid deposition in patients with
DLB who had detailed neuropsychological and clinical
evaluations to assess the impact of amyloid on clinical
profile. We hypothesized that in DLB, a positive amy-
loid PET scan would be associated with clinical and
imaging findings similar to AD, that is, poorer mem-
ory function, hippocampal atrophy, and reduced
medial temporal lobe perfusion. We also hypothesized
that amyloid deposition in DLB would be intermediate
between AD patients and healthy controls.
Methods
Participants
Participants were recruited prospectively between
June 2013 and February 2016 from secondary care serv-
ices in the North of England. Control participants were
recruited through a research case register or were part-
ners of participants. All participants were 60 years
old. Dementia patients had a diagnosis of probable
DLB or probable AD confirmed by 2 clinicians based
on contemporaneous diagnostic criteria,1,5 with an
MMSE 12. The results of amyloid imaging were not
known to the clinicians when making the diagnosis.
Control participants had an MMSE 26 and no signs
of dementia or mild cognitive impairment. DLB patients
were recruited prior to the publication of the 2017 diag-
nostic criteria for DLB,6 but by definition, they would
all satisfy the updated criteria for probable DLB.
Participants were excluded if they had a major con-
current psychiatric illness, severe physical illness, con-
traindications to PET-CT imaging, a history of other
significant neurological illness including stroke, previ-
ous experimental treatment with an amyloid-targeting
agent, or current treatment with any other investiga-
tional agent.
Standard Protocol Approvals, Registrations,
and Patient Consents
Participants with capacity gave their written
informed consent to take part in the study. For those
with dementia who lacked capacity, their participation
in the study was discussed with a consultee in accor-
dance with the Mental Capacity Act. The study
received ethical approval from the National Research
Ethics Service Committee North East—Newcastle &
North Tyneside 2 (Research Ethics Committee Identifi-
cation Number 13/NE/0064).
Baseline Cognitive and Clinical Assessments
A thorough clinical assessment was carried out
including measures of the following:
—Cognitive impairment (Addenbrooke’s Cognitive
Examination-Revised,7 FAS Verbal Fluency,8 Trail
Making Tests A and B,9 Graded Naming Test,10
Rey Auditory Verbal Learning Test,11 and comput-
erized tests of simple and choice reaction times,
digit vigilance, line angle discrimination, and
motion detection12-14)
—Functional impairment (Bristol and Instrumental
Activities of Daily Living Scales15,16)
—Neuropsychiatric symptoms (Geriatric Depres-
sion Scale,17 Clinician Assessment of Fluctua-
tions,18 Dementia Cognitive Fluctuations Scale,19
Neuropsychiatric Inventory20)
—Parkinsonism (revised UPDRS21).
Imaging
Imaging was performed using a Siemens Biograph-40
PET-CT scanner (Siemens, Erlangen) in list mode. Partici-
pants were given a 370 MBq intravenous injection of 18F-
Florbetapir (Amyvid, Avid/Eli Lilly, Cork) followed imme-
diately by a 5-minute scan for perfusion images, with a
15-minute scan (335 minute frames) starting 30 to 50
minutes after injection to image amyloid distribution.
Images were reconstructed using iterative reconstruction
(4 iterations, 16 subsets), with a 1683 168 matrix size,
2.0432.04mm pixel size, 3-mm slice thickness, and 3-
mm postreconstruction Gaussian filter. Attenuation cor-
rection was performed using CT scan data.
CT scans were obtained immediately before the PET
images. CT dose was minimized using the Siemens
CARE Dose 4D protocol with 50 mAsec target dose,
0.5-second gantry rotation time, 0.8-mm beam pitch,
0.6-mm slice thickness, and a scan duration of 19 sec-
onds. Images were reconstructed with 3-mm slice
thickness to match the PET images. For participants
without magnetic resonance imaging (MRI), CT scans
were also reconstructed with a 1-mm slice thickness
for use as a background scan for visual rating.
MRI scans were performed on all patients unless
contraindicated because of metal implants (n57).
Scans were acquired on a 3T whole-body MR scanner
(Achieva scanner; Philips Medical Systems, Eindho-
ven), with body coil transmission and 8-channel head
coil receiver. Images acquired included a 3-
dimentional sagittal magnetization-prepared rapid gra-
dient echo sequence (repetition time 8.3 milliseconds,
echo time 4.6 milliseconds, flip angle 88, inversion
delay 1250 milliseconds, imaging time 4.5 minutes).
The sagittal acquisition matrix was 2163 240, giving
a voxel size of 13 131 mm.
Image Processing
All analyses of MRI and PET images were per-
formed using SPM 8 (www.fil.ion.ucl.ac.uk/spm/soft-
ware/spm8/). A mean amyloid PET image was
obtained by coregistering the 3 5-minute scans under-
taken 30 to 50 minutes postinjection. This mean scan
was then coregistered with the native-space MRI. MRI
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images were segmented into white matter, gray mat-
ter, and CSF. Gray and white matter images were
smoothed using a 4-mm, full-width, half-maximum
Gaussian kernel to match the PET resolution. Region
of interest maps were developed to mirror those used
in the AD Neuroimaging Initiative22 using the Mars-
Bar (www.marsbar.sourceforge.net) region map (Sup-
plementary Table 1).23 In addition to the frontal,
temporal, parietal, cingulate, and cerebellar areas used
in the AD Neuroimaging Initiative, striatal and occipi-
tal regions were also included as imaging findings in
these areas (occipital hypoperfusion and nigrostriatal
denervation) are characteristic of DLB. These maps
were transformed into native space for each partici-
pant. Cortical and white matter areas within these
regions were identified using a threshold of 0.5 on the
smoothed gray and white matter segmentation images.
Mean PET uptake values within the regions of interest
were then determined. Standardized uptake value
ratios (SUVR) were calculated for each region by
dividing the mean uptake in the region by the mean
uptake in the cerebellum. The cerebellum has been the
reference region of choice for cross-sectional data in
the AD Neuroimaging Initiative.24
A mean cortical SUVR was derived from the
unweighted mean of the frontal, temporal, parietal,
and cingulate regions.22
Voxel-Wise Analysis of Images
The mean amyloid PET image was coregistered with
the perfusion PET image for each participant. The per-
fusion PET images were then spatially normalized to
an age-appropriate template,25 and the normalization
parameters were applied to the amyloid images. Both
the amyloid and perfusion images were smoothed with
an 8-mm Gaussian filter, and the images were inten-
sity normalized using the mean of a cerebellum region
of interest.23 This approach of normalizing via the
perfusion scan was used because 7 participants did
not have MRI images.
For the atrophy analysis, the segmented MRI images
were processed using the Diffeomorphic Anatomical
Registration Through Exponentiated Lie Algebra Tool-
box to create a group-specific template and spatially
normalize images to it. The images were modulated to
preserve the total tissue amount during normalization
and smoothed with an 8-mm Gaussian filter.
Perfusion and Atrophy Region of Interest
In a previous paper investigating AD and DLB with
perfusion single-photon emission computed tomography
(SPECT) and fluorodeoxyglucose (FDG) PET, we found
that regions of interest in the parietal lobe (angular
gyrus), medial occipital cortex, and medial temporal
lobe had good specificity and sensitivity for distinguish-
ing between dementia groups.26 We thus used the same
regions to extract mean values from the normalized per-
fusion images. In addition, we determined the volume
of the hippocampus from the gray matter segmentation
using a previously described automated technique.27
Total gray matter, white matter, and CSF volume were
also calculated from the segmentation images, and total
intracranial volume is defined as the sum of these. Hip-
pocampal volume and gray matter volume were ana-
lyzed relative to total intracranial volume.
Visual Rating
Amyloid PET images were reviewed by 5 raters
(J.O., M.F., G.P., J.L., and P.D.), all of whom had
completed certified training in amyloid image reading.
Raters were blinded to all clinical data. Scans were
classified as positive or negative based on the method
developed by the manufacturer.28 All scans were rated
independently, following which a consensus meeting
was held to discuss those scans in which there was dis-
agreement (defined as a 3/2 split) on whether the scan
was positive or negative, and a final group decision
was reached.
Statistical Analysis
Statistical analysis was completed using SPSS Statis-
tics software (version 22; http://www-03.ibm.com/soft-
ware/products/en/spss-statistics; IBM, New York).
Normality was tested using the Shapiro-Wilk test. Com-
parisons between diagnostic groups were carried out
using one-way analysis of variance or Kruskall-Wallis
tests with post hoc pairwise comparisons where signifi-
cant (Bonferroni test a5 .05). v2 or Fisher’s exact tests
were used for categorical variables. Comparisons
between amyloid-positive and amyloid-negative DLB
cases were carried out using the general linear model
and logistic regression; linear regression was used to
investigate associations with mean cortical SUVR. Age
and years in education were included as covariates for
cognitive variables; age, sex, and years in education
were included as covariates for imaging variables.
Voxel-wise analyses were performed on the
smoothed normalized images using the general linear
model in SPM, with covariates of participant age and
sex and (for MRI) total intracranial volume. Signifi-
cant voxels (P< .001 uncorrected) were initially iden-
tified, followed by a cluster-based family-wise error
correction (a5 .05).
Participants with missing data were excluded from
each analysis. The sample size was calculated to allow
the detection of clinically useful differences between
amyloid-positive and amyloid-negative DLB partici-
pants. It was anticipated that approximately 50% of
DLB participants would be amyloid positive. A sample
size of n5 15 to 20 per group would be sufficient to
detect clinically useful differences (>1 SD) between
the groups with 80% power.
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TABLE 1. 18F-Florbetapir SUVR, cortical volume, and perfusion in DLB, AD, and control groups
Imaging Measure Control AD DLB P
Parietal SUVR, mean (SD) 1.10 (0.16) 1.37 (0.19) 1.25 (0.22) .001a
Frontal SUVR, mean (SD) 1.11 (0.19) 1.38 (0.25) 1.25 (0.24) .004a
Temporal SUVR, mean (SD) 1.10 (0.15) 1.36 (0.22) 1.25 (0.21) .001a
Cingulate SUVR, mean (SD) 1.17 (0.21) 1.45 (0.25) 1.32 (0.25) .003a
Occipital SUVR, mean (SD) 1.08 (0.12) 1.27 (0.18) 1.20 (0.18) .002a,b
Striatal SUVR, mean (SD) 1.11 (0.13) 1.28 (0.22) 1.19 (0.17) .01a
Cortical SUVR, mean (SD) 1.12 (0.17) 1.39 (0.22) 1.26 (0.23) .002a
Gray matter vol., mean (SD) 0.39 (0.03) 0.36 (0.03) 0.37 (0.03) <.01a,b
Hippocampal vol., mean (SD) 1.79 (0.20) 1.27 (0.26) 1.49 (0.36) <.001a,b,c
Parietal perf., mean (SD) 1.04 (0.05) 0.87 (0.12) 0.86 (0.10) <.001a,b
MTL perf., mean (SD) 0.79 (0.05) 0.68 (0.08) 0.78 (0.09) <.001a,c
Occipital perf., mean (SD) 1.08 (0.05) 1.02 (0.08) 0.98 (0.07) <.001a,b
Occipital/MTL perf., mean (SD) 1.37 (0.07) 1.52 (0.18) 1.29 (0.17) <.001c
One-way analysis of variance or Kruskall-Wallis tests with post-hoc Bonferroni Correction (a5 0.05). Hippocampal and gray matter volumes are relative to total
intracranial volume. SUVR measures: AD n5 19, DLB n5 31; volume measures: DLB531; otherwise control n5 20, AD n5 20, DLB n5 37. DLB, dementia
with Lewy bodies; AD, Alzheimer’s disease; SUVR, Standardized Uptake Value Ratio; vol., volume, perf., perfusion, MTL, medial temporal lobe.
aSignificant difference control versus AD.
bSignificant difference control versus DLB.
cSignificant difference AD versus DLB.
TABLE 2. Demographics and cognitive and clinical scales amyloid-positive and amyloid-negative dementia with Lewy bod-
ies groups on visual rating
Amyloid negative, n5 17 Amyloid positive, n520 P
Age, mean (SD), years 75.7 (5.6) 76.3 (7.3) .78
Duration of dementia, mean (SD), months 25.9 (23.8) 20.5 (17.9) .54
Sex, no. female (%) 3 (18) 3 (15) 1
Years in education, mean (SD) 10.3 (3.6) 12.6 (3.4) .05
AChI/mem., no. (%) 16 (94) 20 (100) .46
Antipsychotic, no. (%) 2 (12) 2 (10) 1
APOE e4, no. (%) 8 (47) 13 (68) .19
ACE-R Total, mean (SD) 61.9 (13.3) 64.9 (16.5) .83
ACE-R Att./orient., mean (SD) 12.7 (3.6) 13.9 (3.2) .52
ACE-R Memory, mean (SD) 13.1 (4.8) 13.2 (6.0) .36
ACE-R Fluency, mean (SD) 5.2 (2.8) 6.8 (3.1) .38
ACE-R Language, mean (SD) 21.1 (3.4) 22.2 (2.8) .95
ACE-R Visuospatial, mean (SD) 9.9 (3.5) 8.9 (4.0) .38
Rey Delayed Recall, mean (SD) 2.2 (2.8) 1.7 (2.4) .22
Failed Trails A, no. (%) 8 (47) 6 (30) .45
Failed Trails B, no. (%) 13 (77) 17 (85) .24
FAS, mean (SD) 18.5 (12.2) 25.4 (12.9) .44
GNT, mean (SD) 14.2 (7.8) 14.8 (8.3) .46
IADL, mean (SD) 3.5 (2.3) 3.2 (2.0) .75
BADL, mean (SD) 18.8 (12.9) 18.6 (13.2) .80
NPI Hallucinations, mean (SD) 2.3 (2.4) 2.7 (2.8) .92
NPI Hallucinations Distress, mean (SD) 0.8 (1.2) 0.8 (1.3) .68
NPI Total, mean (SD) 15.9 (10.5) 24.1 (25.1) .25
NPI Distress total, mean (SD) 7.2 (8.0) 10.2 (11.3) .45
DCFS, mean (SD) 11.9 (4.0) 10.9 (3.8) .50
CAF, mean (SD) 5.1 (4.2) 7.3 (4.5) .07
GDS 5.1 (2.7) 4.5 (2.7) .30
MDS-UPDRS motor, mean (SD) 40.8 (16.5) 46.2 (18.4) .58
Lying–standing sys. BP, mean (SD), mmHg 216.1 (25.3) 213.3 (24.1) .30
Lying–standing dias. BP, mean (SD), mmHg 21.3 (9.1) 21.7 (10.4) .64
General linear model for cognitive and clinical tests with continuous measures and logistic regression for dichotomous outcome variables with age and years
in education as covariates. APOE e4: amyloid positive n519; Rey Delayed Recall: amyloid positive n518; NPI Distress: amyloid positive n5 19; BP: amyloid
negative n5 15, amyloid positive n5 18. AChI/mem., on acetylcholinesterase inhibitor or memantine; APOE e4, 1 e4 allele; ACE-R, Addenbrooke’s Cognitive
Examination Revised; Att./orient, attention/orientation; FAS, FAS Verbal Fluency; GNT, Graded naming test; IADL, Instrumental Activities of Daily Living Scale;
BADL, Bristol Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory; DCFS, Dementia Cognitive Fluctuations Scale; CAF, Clinician Assessment of
Fluctuation; GDS, Geriatric Depression Scale; MDS-UPDRS, Unified Parkinson’s Disease Rating Scale motor subscale; BP, blood pressure.
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Results
Comparison of DLB, AD, and Controls
A total of 87 volunteers agreed to enter the study,
of which 77 met the eligibility criteria and completed
their assessment. Supplementary Table 2 summarizes
the group characteristics. The groups were well
matched for age and sex, and the dementia groups
were well matched for level of cognitive impairment.
DLB cases performed more poorly than controls on all
cognitive tests (Supplementary Tables 2 and 3). The only
difference between DLB and AD on cognitive testing was
the digit vigilance task, with DLB cases displaying worse
attention (digit vigilance number correct P5 .01).
The proportion of DLB cases with a positive-
amyloid PET scan on visual rating was 20/37 (54%).
This was significantly higher than controls (4/20
[20%]; P5 .01), but significantly lower than AD (17/
20 [85%]; P5 .02).
Mean cortical amyloid deposition in DLB was inter-
mediate between AD and controls, although it was not
significantly different from either group (Table 1). DLB
cases had higher amyloid deposition in occipital lobes
when compared with controls (P5 .04). Amyloid depo-
sition was significantly higher in AD than controls in
every cortical region, but there were no significant dif-
ferences between AD and DLB cases in any region.
SPM analysis of amyloid PET images found wide-
spread amyloid deposition in AD when compared
with controls, particularly in the frontal, temporal,
and parietal areas (Supplementary Figure 1A). Deposi-
tion in DLB was less marked, but followed a similar
distribution (Supplementary Figure 1B). There were
few areas of higher deposition in AD when compared
with DLB (Supplementary Figure 1C), none of which
survived family-wise error correction for significant
clusters, although an occipital cluster approached sig-
nificance (P5 .052).
When compared with AD, the DLB group displayed
higher hippocampal volume (P5 .04), greater medial tem-
poral lobe perfusion (P< .001), and a lower occipital:me-
dial temporal lobe perfusion ratio (P< .001; Table 1).
On voxel-wise analysis, when compared with controls,
the DLB patients displayed temporoparietal atrophy and
posterior hypoperfusion, with AD cases displaying more
widespread atrophy and temporoparietal hypoperfusion
(Supplementary Figure 2). DLB patients had less left
medial temporal lobe atrophy, higher medial temporal
and orbitofrontal perfusion, and lower perfusion in a
part of the occipital cortex when compared with the AD
patients (Supplementary Figure 3).
Comparison of Amyloid-Positive and Amyloid-
Negative DLB Patients
The amyloid-positive and amyloid-negative DLB
groups were similar in age, although the amyloid-
positive group approached having significantly more
years in education (P5 .05; Table 2). There were no
statistically significant differences in any clinical or
cognitive test (Table 2, Supplementary Table 4). There
was no difference between the 2 groups in duration of
dementia (time from diagnosis to baseline assessment).
There were no differences between the amyloid-
positive and amyloid-negative DLB groups in hippo-
campal volume or total gray matter volume (P> .20;
Table 3). However, the amyloid positive group dis-
played lower medial temporal lobe perfusion (P5 .03)
There were no differences between amyloid-positive
and amyloid-negative DLB cases in atrophy or perfu-
sion on voxel-based analysis.
Correlation of Semiquantification of Amyloid
Deposition With Clinical and Imaging Findings
in DLB
When entered into linear regression with age and
years in education, there was no correlation between
mean cortical SUVR and any symptom scale or cogni-
tive test (P> .05) apart from an association with
increased cortical SUVR and lower simple reaction
time (b52.57, t522.95, P< .01) and lower simple
TABLE 3. Comparison of atrophy and perfusion between
amyloid-positive and amyloid-negative dementia with
Lewy bodies groups on visual rating
Imaging Measure
Amyloid
negative
Amyloid
positive P
Gray matter volume, mean (SD) 0.37 (0.02) 0.37 (0.03) .60
Hippocampal volume, mean (SD) 1.52 (0.25) 1.46 (0.45) .55
Parietal perfusion, mean (SD) 0.87 (0.12) 0.85 (0.09) .51
Occipital perfusion, mean (SD) 0.98 (0.08) 0.99 (0.05) .93
MTL perfusion, mean (SD) 0.80 (0.05) 0.75 (0.10) .03
Occipital:MTL perfusion,
mean (SD)
1.23 (0.15) 1.33 (0.19) .049
General linear model with age, sex, and years in education as covariates.
Hippocampal and gray matter volumes are relative to total intracranial vol-
ume. Volume measures: amyloid negative n5 15, amyloid positive n5 16;
perfusion measures: amyloid negative n5 17, amyloid positive n5 20. MTL,
medial temporal lobe.
TABLE 4. Relationship of mean cortical Florbetapir SUVR
to cortical atrophy and perfusion
Imaging Measure b (95% CI) P
Hippocampal vol. 20.29 (20.60 to 0.03) .07
Gray matter vol. 0.15 (20.23 to 0.53) .42
Parietal perf. 0.21 (20.23 to 0.65) .33
Occipital perf. 0.34 (20.12 to 0.81) .14
MTL perf. 20.52 (20.87 to 20.17) .005
Occipital:MTL perf. 0.65 (0.34 to 0.96) <.001
Linear regression with mean cortical Florbetapir SUVR, age, sex, and years
in education included as independent variables. Hippocampal and gray
matter volumes are relative to total intracranial volume. SUVR, Standard-
ized Uptake Value Ratio; vol., volume; MTL, medial temporal lobe; perf.,
perfusion.
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reaction time coefficient of variation (b52.46,
t522.14, P5 .04). There was no significant correla-
tion between mean cortical SUVR and Neuropsychiat-
ric Inventory hallucinations, Clinician Assessment of
Fluctuations, Dementia Cognitive Fluctuations Scale,
or UPDRS total, gait, rigidity, rest tremor, or postural
stability scores.
When entered into linear regression with age, sex,
and years in education as independent variables,
increased amyloid deposition was associated with
lower medial temporal lobe perfusion (b52.52,
t523.07, P5 .005) and a higher occipital:medial
temporal lobe ratio (b5 .65, t54.30, P< .001; Table
4). There was a trend toward an association with
lower hippocampal volume (b52.29, t521.87,
P5 .07).
Striatal amyloid deposition has been linked to the
severity of cognitive impairment in postmortem stud-
ies.29 We found that higher striatal SUVR was associ-
ated with lower simple reaction time (b52.45,
t522.2, P5 .03). There were no significant associa-
tions between striatal SUVR and any other cognitive
test or measure of functional impairment.
Analysis of voxel-based correlation between mean
cortical amyloid deposition and gray matter density
found no statistically significant clusters. However,
there was an almost significant cluster of negative cor-
relation between amyloid deposition and perfusion in
the right hippocampus (P5 .07, family-wise error
cluster-wise corrected; Fig. 1).
Identifying Amyloid-Positive DLB Cases With-
out Amyloid Imaging
A post hoc discriminant analysis was carried out to
test whether amyloid-positive DLB cases could be iden-
tified without amyloid imaging. A simple model of age
and medial temporal lobe perfusion yielded a sensitivity
of 60% and specificity of 65% (Wilk’s lambda P5 .22)
to identify amyloid-positive cases. A model of age and
occipital:medial temporal lobe perfusion gave a lower
sensitivity (50%) but the same specificity (Wilk’s
lambda P5 .18). A more complex model including age,
medial temporal lobe perfusion, hippocampal volume,
years in education, simple reaction time, and simple
reaction time coefficient of variation yielded a sensitiv-
ity of 73% and a specificity of 64% (Wilk’s lambda
P5 .07).
Discussion
Amyloid Deposition and Clinical Profile in DLB
Previous evidence, particularly from postmortem
studies, has suggested that amyloid deposition in DLB
may be associated with greater cognitive impair-
ment,30 fewer core features of DLB,31 and greater
brain atrophy.32 We hypothesized that amyloid-
positive DLB patients would have a clinical profile
with similarities to AD, in particular greater memory
impairment. However, we found no difference
between amyloid-positive and amyloid-negative DLB
cases on any cognitive test or measure of neuropsychi-
atric features, fluctuations, or parkinsonism. It is clear
from our findings that it is not possible to identify the
presence or absence of amyloid pathology in cases of
probable DLB based on clinical profile. Direct mea-
surement of amyloid through PET imaging or CSF
measurement will be required for any research project
wishing to identify DLB patients with concomitant
amyloid deposition.
The lack of correlation between amyloid deposition
and clinical profile may in part be because 18F-Florbe-
tapir binds to both neuritic and diffuse plaques. In
contrast, pathological studies have reported associa-
tions between clinical profile and neuritic plaques
only,31 or combined amyloid and neurofibrillary tan-
gle pathology.32 Another factor may be that amyloid
is an “upstream” factor in a cascade of events leading
to neuronal damage and clinical symptoms.33 In this
hypothesis, the severity of amyloid deposition would
not reflect disease stage, but the presence of amyloid
would be expected to be associated with more rapid
disease progression. A recent study investigating CSF
biomarkers in DLB found no baseline differences in
cognition between those with an AD CSF profile and
those with a normal profile.34 However, they did find
that abnormal amyloid levels in CSF were associated
with more rapid cognitive decline during follow-up.
FIG. 1. Voxel-based correlation of amyloid deposition and perfusion in dementia with Lewy bodies. In uncorrected images (P<.001) there were 2 occipi-
tal clusters of positive correlation between amyloid deposition and perfusion and 2 hippocampal clusters of negative correlation. Following family-wise
error correction (not displayed), the right hippocampal cluster approached significance (P5.07). [Color figure can be viewed at wileyonlinelibrary.com]
D O N A G H Y E T A L
6 Movement Disorders, Vol. 00, No. 00, 2018
In contrast, tau pathology may be a “downstream”
factor in this cascade and has previously been found
to be less prevalent than amyloid pathology in DLB,
but more closely related to clinical presentation.35
Early data from tau imaging studies have reported
conflicting findings on the relationships between amy-
loid deposition, tau deposition, and clinical profile in
DLB.36,37 Other important pathophysiological factors
such as the extent and severity of Lewy body pathol-
ogy remain unquantifiable until postmortem.
Amyloid Deposition and Imaging Variables in
DLB
Amyloid-positive DLB patients had lower medial
temporal lobe perfusion, and there was a significant
inverse correlation between mean cortical SUVR and
medial temporal lobe perfusion. A trend toward an
association between amyloid deposition and hypoper-
fusion was also observed in the right hippocampus on
voxel-based correlation. Two studies have reported
negative findings when comparing amyloid-positive
and amyloid-negative DLB cases with FDG uptake,
although these studies had smaller sample sizes
(n5 1038 and n5 2139).
There was no difference between amyloid-positive
and amyloid-negative DLB patients in gray matter vol-
ume in region of interest and voxel-based analyses.
There was, however, a trend toward an inverse corre-
lation between mean cortical Florbetapir SUVR and
hippocampal volume. A recent longitudinal study
found an association between baseline amyloid deposi-
tion and rates of decline in gray matter volume in pos-
terior cingulate, temporal, medial temporal, and
occipital regions, with the strongest association seen in
the medial temporal lobe.40 As a result of the rela-
tively subtle degree of atrophy observed in DLB, dif-
ferences in atrophy between amyloid-positive and
amyloid-negative patients may be difficult to detect in
cross-sectional analyses.
Our findings, along with the previous reported asso-
ciation between amyloid deposition and rates of brain
atrophy, suggest that although there is little evidence
of an association between amyloid deposition and an
AD-like clinical profile in DLB, amyloid is associated
with imaging evidence of neurodegenerative changes
in the brain, particularly in the medial temporal lobes.
This could be because of the additive effects of amy-
loid pathology in DLB, the presence of tau pathology
associated with amyloid, and/or synergistic interac-
tions between amyloid/tau and a-synuclein. MRI stud-
ies with postmortem confirmation have demonstrated
a correlation between hippocampal atrophy and both
amyloid and neurofibrillary tangle pathology.41,42
Conversely, Lewy body pathology was found not to
correlate with hippocampal volume,42 although a-
synuclein burden may decrease following cell death,
making any such association difficult to detect.43
There is also evidence for synergistic interactions
between AD pathology and a-synuclein. Amyloid
deposition has been associated with greater Lewy
body pathology in Lewy body disease (Parkinson’s dis-
ease and Lewy body dementia).44 Preclinical models
have shown that the presence of tau promotes the
fibrillization of a-synuclein45 and that the presence of
a-synuclein increases the deposition of tau and amy-
loid in transgenic mice.46 Combined tau and amyloid
imaging studies may help to clarify the contributions
of each pathology to atrophy in DLB, although in the
absence of an a-synuclein imaging ligand the contribu-
tion of synergistic effects may be difficult to
determine.
Comparison of Amyloid Imaging Across
Disease Groups
Consistent with previous research47 a positive amy-
loid PET scan on visual rating was more common in
DLB than controls, but less common than in AD. On
semiquantitative measurement, only the occipital lobes
demonstrated significantly greater Florbetapir binding
in DLB than controls, with no significant difference
between DLB and AD or controls in any other region.
However, in every region, DLB had binding values
that were intermediate between controls and AD.
Strengths and Limitations
This article presents the largest and most thoroughly
profiled group of DLB cases to undergo amyloid imag-
ing. We obtained a measure of brain perfusion
through early Florbetapir imaging. This method has
been shown to correlate with FDG-PET imaging.48
The pattern of perfusion observed in this cohort was
similar to that observed with hexamethylpropylenea-
mineoxime perfusion SPECT in a different cohort in
this center.26
A total of 6 DLB patients and 1 AD patient were
unable to have MRI scans as a result of metal
implants. The same AD patient could only tolerate a
5-minute amyloid PET scan. Their scan was not used
in the quantitative analysis, but blinded to clinical
diagnosis, and all 5 raters felt confident to visually
rate the scan as positive. Some patients did not have
complete data, principally as result of an inability to
complete 1 or more parts of the cognitive assessment.
A total of 3 AD patients had negative amyloid PET
scans. However, the proportion of cases with negative
scans is in keeping with previous clinical samples in
AD.47 A repeat analysis of clinical and cognitive com-
parisons was undertaken with the 3 amyloid-negative
AD patients removed from the dataset. The findings
were unchanged. We also compared amyloid-positive
DLB and amyloid-positive AD cases; there were no
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substantial differences to the findings of the overall
comparison between DLB and AD.
We cannot exclude the possibility that the amyloid-
positive control cases reflect preclinical AD. Excluding
these cases would increase the difference between DLB
and controls, but the findings would be less generaliz-
able to the general population.
Selection bias is an important factor to consider
when interpreting these results. The DLB group in this
cohort was typical of other cohorts in the literature
and is reflective of cases of clinically diagnosed DLB.
However, people with concomitant Lewy body and
AD pathology who do not display the diagnostic
symptoms of DLB will not be recruited into DLB
groups in research studies. Thus, clinical samples of
DLB may be more homogeneous in their clinical
symptoms than pathological samples.
Conclusion
We found no evidence for an association between
amyloid deposition and clinical profile in this well-
characterized cohort. However, cortical amyloid depo-
sition was associated with lower medial temporal lobe
perfusion and a trend toward hippocampal atrophy.
This may be a result of synergistic interactions
between amyloid and a-synuclein, additive effects of
the 2 separate pathologies, or interactions between
these proteins and other pathological proteins such as
tau. As such, amyloid remains a potential treatment
target in cases of DLB with substantial amyloid depo-
sition. However, it will not be possible to identify
such cases on clinical, cognitive, or other imaging
grounds, and direct measurement of amyloid either
through imaging or CSF analysis will be needed.
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